Dermatologic Common (1% to 10%): Hair loss, rash, urticaria Postmarketing reports : Alopecia, angioedema, rash, urticaria Hair loss was reported in up to 5.8% of treated patients vs 1% placebo, with higher incidence associated with greater weight loss (20% or more)
This could represent an important secondary advantage for RA patients, who face elevated cardiovascular risk due to chronic inflammation
For early timeline expectations, the semaglutide speed guide and the tirzepatide speed guide provide week-by-week benchmarks
#selfcareroutine This combo is so worth it
LC-MS/MS measurements were performed using a QTRAP 6500 mode (AB Sciex, CA, USA) equipped with a Turbo V electrospray ion source and coupled to a Perkin Elmer Series 200 micro-LC system (Massachusetts, USA)
doi: 10.1182/blood-2016-10-569186 [DOI] [PubMed] [Google Scholar] 77.Olesen J, Thomsen L, Lassen L, Olesen I